![]() |
市場調查報告書
商品編碼
2085154
血液採集市場:全球市場按產品類型、技術、應用和最終用戶分類的預測-2026-2032年Blood Collection Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,血液採集市場規模將達到 220.5 億美元,複合年成長率為 7.15%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 135.9億美元 |
| 預計年份:2026年 | 143.2億美元 |
| 預測年份 2032 | 220.5億美元 |
| 複合年成長率 (%) | 7.15% |
血液採集在輸血醫學、診斷檢測、血漿分餾、急診醫學和慢性病管理中發揮核心作用。該市場涵蓋靜脈和毛細血管採血裝置、血袋、真空採血管、針頭、採血針、安全套裝、血漿採集系統以及醫院、診斷檢查室、血庫、移動採血車和門診診所使用的預分析工作流程解決方案。
血液採集領域正從以血量為中心的採集方式轉向以安全、自動化和數據驅動的工作流程為重點。醫療機構優先考慮密封系統、針頭安全、一次性無菌耗材、條碼追溯、標準化採血管處理以及經過驗證的預分析流程,以減少檢體不相容性、職業暴露、污染風險和檢驗相關錯誤。
人工智慧 (AI) 透過需求預測、捐血排班、庫存分配、最佳化採血流程、靜脈可視化支援、移動採血路線規劃和自動化品質檢查,對血液採集作業產生日益顯著的影響。 AI 驅動的分析功能使血站和醫院能夠根據血液使用模式、血液成分保存期限限制、血型需求和緊急應變要求來調整採血活動,從而減少血液短缺和浪費。
亞太地區擁有龐大的病患群體,診斷網路不斷擴展,外科手術量持續成長,中國、印度、日本、澳洲和韓國等國均推行政府主導的血液安全計畫。各國積極開展自願捐血、血液篩檢和提升檢查室認證水平,推動了對可靠的採血管、血袋、安全針頭以及符合低溫運輸要求的血液採集流程的需求。北美地區擁有高度普及的安全型血液採集設備,這得益於先進的醫院基礎設施、美國食品藥物管理局(FDA)和加拿大衛生署的監管、成熟的實驗室網路以及完善的感染預防政策和職業安全要求。
在東協市場,印尼、泰國、越南、馬來西亞、新加坡和菲律賓的血液採集系統正隨著醫院現代化、監管協調以及診斷檢測需求的成長而不斷發展。這些國家正在加強血庫營運、感染控制措施,並確保高品質血液採集耗材的供應,同時力求在價格可負擔性與國際標準之間取得平衡。在海灣合作理事會(GCC)國家,重點在於建造高品質的醫院基礎設施、推進國家醫療衛生轉型計畫、提升緊急應變能力,並實行集中採購,優先採購符合監管規定的高品質血液採集設備、無菌耗材和數位化溯源工具。
美國食品藥物管理局醫療設備、大規模的血液中心網路、職業安全標準以及以安全為中心的血液採集系統的快速部署,在行業中處於領先地位。加拿大則強調全國各地的血液服務協調、品質保證、捐血安全和標準化的輸血流程。同時,墨西哥和巴西正透過投資醫院、推動公共衛生現代化以及改善血庫基礎設施來擴大血液供應。英國、德國、法國、義大利和西班牙擁有成熟的檢測和輸血系統,這些系統以嚴格的標準、認證系統、集中採購以及對可靠的真空採血管、血袋、針頭和分析前品管解決方案的持續需求為支撐。
業界領導者應優先考慮安全性至上的醫療設備、分析前品質、捐血和患者的舒適度以及與自動化檢測流程的兼容性。產品系列必須既能滿足高通量醫院環境的需求,又能滿足分散式血液採集模式的需求,包括毛細血管採集、移動捐血、血漿採集、居家檢體採集和即時診斷。
本調查方法结合了来自公共卫生、监管、临床、标准和行业领域的檢驗二手信息以及系统的市场檢驗。主要參考文獻包括世界衛生組織關於血液安全和供應的指南、美國食品藥物管理局(FDA)的醫療設備需求、美國疾病管制與預防中心(CDC)的感染預防資源、國際標準化組織(ISO)標準、臨床實驗室標準協會(CLSI)指南、國家血液服務機構的出版刊物、公共採購文件、臨床實驗室標準以及關於輸血醫學和分析前品質的同儕輸血醫學和分析前品質的審查文獻。
血液採集仍是安全診斷、輸血、血漿療法、產科、癌症治療、外科手術、急診醫學和公共衛生監測的基礎。市場趨勢受安全需求、不斷成長的檢測需求、醫院現代化、捐血管理需求、感染預防政策以及向網路化、自動化和以患者為中心的血液採集模式轉變等因素的影響。
The Blood Collection Market is projected to grow by USD 22.05 billion at a CAGR of 7.15% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 13.59 billion |
| Estimated Year [2026] | USD 14.32 billion |
| Forecast Year [2032] | USD 22.05 billion |
| CAGR (%) | 7.15% |
Blood collection is a core enabler of transfusion medicine, diagnostic testing, plasma fractionation, emergency care, and chronic disease management. The market spans venous and capillary blood collection devices, blood bags, evacuated tubes, needles, lancets, safety sets, plasma collection systems, and preanalytical workflow solutions used across hospitals, diagnostic laboratories, blood banks, mobile collection units, and ambulatory care settings.
Demand is supported by the rising burden of cancer, cardiovascular disease, kidney disease, trauma care, maternal health needs, infectious disease surveillance, and routine laboratory testing. Verified public health guidance from the WHO, FDA, CDC, ISO, CLSI, and national blood services continues to shape procurement priorities around sterility, traceability, donor safety, hemolysis reduction, specimen integrity, occupational exposure prevention, and transfusion-transmitted infection control.
The blood collection landscape is shifting from volume-based procurement toward safety, automation, and data-connected workflows. Healthcare providers are prioritizing closed systems, needle safety, single-use sterile consumables, barcode-based traceability, standardized tube handling, and validated preanalytical processes to reduce specimen rejection, occupational exposure, contamination risk, and transfusion-related errors.
Another transformative shift is the expansion of decentralized and patient-centered collection. Capillary blood collection, home-based sampling models, mobile donation drives, and point-of-care testing are changing how samples and blood products enter the healthcare system. Manufacturers that combine ergonomic design, regulatory compliance, automation readiness, sustainable packaging, and digital inventory visibility are gaining strategic relevance in blood collection procurement.
Artificial intelligence is increasingly influencing blood collection through demand planning, donor scheduling, inventory allocation, phlebotomy workflow optimization, vein visualization support, route planning for mobile drives, and automated quality checks. AI-enabled analytics can help blood centers and hospitals reduce shortages and wastage by aligning collection activity with utilization patterns, component shelf-life constraints, blood group demand, and emergency preparedness requirements.
The cumulative impact is operational rather than purely technological: faster triage, improved donor engagement, better staffing decisions, earlier detection of collection anomalies, and improved specimen integrity. Adoption must remain evidence-led, with validated algorithms, human oversight, cybersecurity controls, privacy safeguards, explainable decision logic, and bias monitoring embedded into blood service governance and laboratory quality management systems.
Asia-Pacific is shaped by large patient populations, expanding diagnostic networks, rising surgical volumes, and government-backed blood safety programs across China, India, Japan, Australia, and South Korea. National efforts to improve voluntary donation, blood screening, and laboratory accreditation are strengthening demand for reliable blood collection tubes, blood bags, safety needles, and cold-chain-compatible collection workflows. North America benefits from advanced hospital infrastructure, FDA and Health Canada oversight, mature laboratory networks, and strong adoption of safety-engineered blood collection devices, supported by established infection prevention policies and occupational safety requirements.
Latin America, led by Brazil and Mexico, is modernizing blood banking capacity while addressing uneven access across urban and rural settings, creating demand for cost-effective, compliant, and durable blood collection consumables. Europe is guided by strict quality systems, CE-marked medical technologies, ISO-aligned laboratory practices, and regional blood, tissue, and cell safety frameworks that emphasize traceability, donor protection, and product conformity. The Middle East is investing in hospital expansion, medical tourism, emergency care readiness, and centralized procurement, while Africa remains focused on WHO-aligned safe blood access, screening capacity, cold-chain reliability, rural collection coverage, and workforce training to reduce preventable transfusion risks.
ASEAN markets are advancing blood collection through hospital modernization, regulatory harmonization efforts, and growing demand for diagnostic testing across Indonesia, Thailand, Vietnam, Malaysia, Singapore, and the Philippines. These countries are strengthening blood bank operations, infection control practices, and access to quality collection consumables while balancing affordability with international standards. The GCC is emphasizing premium hospital infrastructure, national health transformation programs, emergency response capacity, and centralized purchasing that favors compliant, high-quality blood collection devices, sterile consumables, and digital traceability tools.
The European Union remains a benchmark for safety, traceability, and product conformity through harmonized medical device regulation, blood safety requirements, and strong quality management expectations. BRICS countries combine large demand pools with domestic manufacturing ambitions, public hospital expansion, and growing emphasis on supply-chain resilience for blood collection tubes, bags, needles, and plasma-related systems. G7 markets are leading in automation, digital health integration, laboratory accreditation, donor management, and occupational safety adoption. NATO countries increasingly evaluate blood collection and transfusion readiness as part of emergency preparedness, battlefield medicine, trauma response, disaster planning, and resilient medical supply chains.
The United States leads through high testing volumes, FDA-regulated medical devices, large blood center networks, occupational safety standards, and rapid adoption of safety-engineered blood collection systems. Canada emphasizes coordinated national blood services, quality assurance, donor safety, and standardized transfusion practices, while Mexico and Brazil are expanding access through hospital investment, public health modernization, and improved blood bank infrastructure. The United Kingdom, Germany, France, Italy, and Spain maintain mature laboratory and transfusion systems supported by strong standards, accreditation practices, centralized procurement discipline, and sustained demand for reliable evacuated tubes, blood bags, needles, and preanalytical quality solutions.
Russia is strengthening domestic supply resilience and healthcare self-sufficiency, while China and India combine large-scale healthcare demand with expanding local manufacturing, rising diagnostic utilization, and government efforts to improve blood safety and hospital capacity. Japan and South Korea emphasize precision, automation, quality control, and laboratory efficiency in clinical diagnostics and transfusion services. Australia benefits from advanced blood service governance, robust quality systems, and geographic logistics expertise, supporting reliable collection, testing, storage, and distribution across dispersed populations and remote care settings.
Industry leaders should prioritize safety-engineered devices, preanalytical quality, donor and patient comfort, and compatibility with automated laboratory workflows. Product portfolios should address both high-throughput hospital environments and decentralized collection models, including capillary sampling, mobile blood donation, plasma collection, home-based sample collection, and point-of-care diagnostics.
Commercial teams should align launches with local regulatory requirements, reimbursement realities, blood service procurement cycles, laboratory accreditation needs, and workforce training requirements. Partnerships with hospitals, reference laboratories, blood centers, public health agencies, and digital health vendors can strengthen differentiation through education, traceability, inventory analytics, cold-chain visibility, and measurable reductions in sample rejection, hemolysis, contamination, and needlestick exposure.
The research methodology combines secondary research from verified public health, regulatory, clinical, standards, and trade sources with structured market validation. Key references include WHO guidance on blood safety and availability, FDA medical device requirements, CDC infection prevention resources, ISO standards, CLSI guidance, national blood service publications, public procurement documents, clinical laboratory standards, and peer-reviewed literature on transfusion medicine and preanalytical quality.
Insights are triangulated across product categories, end users, procurement patterns, regional policy environments, blood safety programs, regulatory developments, and technology adoption signals. The approach emphasizes data reliability, source transparency, and practical relevance for executives evaluating blood collection devices, sterile consumables, automation, donor management systems, plasma collection workflows, and digital traceability investments.
Blood collection remains foundational to safe diagnosis, transfusion, plasma-derived therapies, maternal care, oncology treatment, surgery, emergency medicine, and public health surveillance. Market momentum is being shaped by safety requirements, rising testing demand, hospital modernization, donor management needs, infection prevention policies, and the transition toward connected, automated, and patient-friendly collection models.
Organizations that combine regulatory rigor, evidence-based design, supply-chain resilience, user training, and digital workflow intelligence will be best positioned to compete. The strongest opportunities will come from solutions that improve donor and patient experience while supporting reliable specimen quality, traceability, sterility, occupational safety, and timely clinical decision-making.